AU2010308524B2 - Compounds and compositions as TLR activity modulators - Google Patents

Compounds and compositions as TLR activity modulators Download PDF

Info

Publication number
AU2010308524B2
AU2010308524B2 AU2010308524A AU2010308524A AU2010308524B2 AU 2010308524 B2 AU2010308524 B2 AU 2010308524B2 AU 2010308524 A AU2010308524 A AU 2010308524A AU 2010308524 A AU2010308524 A AU 2010308524A AU 2010308524 B2 AU2010308524 B2 AU 2010308524B2
Authority
AU
Australia
Prior art keywords
compound
formula
amino
naphthyridin
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010308524A
Other languages
English (en)
Other versions
AU2010308524A1 (en
Inventor
Alex Cortez
Yongkai Li
Manmohan Singh
David Skibinski
Tom Yao-Hsiang Wu
Kathy Yue
Xiaoyue Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43625759&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2010308524(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2010308524A1 publication Critical patent/AU2010308524A1/en
Application granted granted Critical
Publication of AU2010308524B2 publication Critical patent/AU2010308524B2/en
Assigned to NOVARTIS AG reassignment NOVARTIS AG Request for Assignment Assignors: IRM LLC, NOVARTIS AG
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2010308524A 2009-09-02 2010-09-01 Compounds and compositions as TLR activity modulators Active AU2010308524B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23921709P 2009-09-02 2009-09-02
US61/239,217 2009-09-02
PCT/US2010/047587 WO2011049677A1 (en) 2009-09-02 2010-09-01 Compounds and compositions as tlr activity modulators

Publications (2)

Publication Number Publication Date
AU2010308524A1 AU2010308524A1 (en) 2012-04-19
AU2010308524B2 true AU2010308524B2 (en) 2014-03-20

Family

ID=43625759

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010308524A Active AU2010308524B2 (en) 2009-09-02 2010-09-01 Compounds and compositions as TLR activity modulators

Country Status (27)

Country Link
US (2) US9045470B2 (forum.php)
EP (1) EP2473508B1 (forum.php)
JP (1) JP5525614B2 (forum.php)
CN (1) CN102712636B (forum.php)
AR (1) AR078153A1 (forum.php)
AU (1) AU2010308524B2 (forum.php)
BR (1) BR112012004696B8 (forum.php)
CA (1) CA2772657C (forum.php)
CL (1) CL2012000535A1 (forum.php)
CY (1) CY1119618T1 (forum.php)
DK (1) DK2473508T3 (forum.php)
EA (1) EA020962B1 (forum.php)
ES (1) ES2627669T3 (forum.php)
HR (1) HRP20170707T1 (forum.php)
HU (1) HUE032323T2 (forum.php)
IN (1) IN2012DN02736A (forum.php)
JO (1) JO3257B1 (forum.php)
LT (1) LT2473508T (forum.php)
MX (1) MX2012002654A (forum.php)
PE (1) PE20121156A1 (forum.php)
PL (1) PL2473508T3 (forum.php)
PT (1) PT2473508T (forum.php)
SI (1) SI2473508T1 (forum.php)
SM (1) SMT201700276T1 (forum.php)
TW (1) TWI445708B (forum.php)
UY (1) UY32874A (forum.php)
WO (1) WO2011049677A1 (forum.php)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10149889B2 (en) 2005-11-25 2018-12-11 Rutgers, The State University Of New Jersey Compositions for the treatment of cancer, and methods for testing and using the same
WO2012125942A1 (en) * 2011-03-16 2012-09-20 University Of Medicine And Dentistry Of New Jersey Combination therapy with leukotoxin
US8926990B2 (en) 2009-10-13 2015-01-06 Rutgers, The State University Of New Jersey Treatment and diagnosis of inflammatory disorders and HIV
PT2818469T (pt) 2008-12-09 2017-05-05 Gilead Sciences Inc Intermediários para a preparação de moduladores de recetores do tipo toll
DK2459216T3 (da) 2009-09-02 2013-12-09 Novartis Ag Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
JP5814933B2 (ja) 2009-12-15 2015-11-17 ノバルティス アーゲー 免疫増強化合物の均質な懸濁物およびその使用
EP2402028A1 (en) * 2010-07-01 2012-01-04 Sanofi Pasteur Enterovirus vaccines for preventing and treating type 1 diabetes (II)
BR112013000244A2 (pt) 2010-07-06 2016-05-17 Novartis Ag lipossomas com lipídeos apresentando pka vantajoso para administração de rna
LT3243526T (lt) 2010-07-06 2020-02-10 Glaxosmithkline Biologicals S.A. Rnr pristatymas, skirtas keleto imuninio atsako paleidimui
PT2591114T (pt) 2010-07-06 2016-08-02 Glaxosmithkline Biologicals Sa Imunização de mamíferos de grande porte com doses baixas de arn
ES2935009T3 (es) 2010-08-31 2023-03-01 Glaxosmithkline Biologicals Sa Liposomas pegilados para la administración de ARN que codifica para inmunógeno
US9315530B2 (en) 2010-09-01 2016-04-19 Novartis Ag Adsorption of immunopotentiators to insoluble metal salts
JP2013544504A (ja) 2010-10-11 2013-12-19 ノバルティス アーゲー 抗原送達プラットフォーム
KR20140026392A (ko) 2011-03-02 2014-03-05 노파르티스 아게 저용량의 항원 및/또는 보조제를 갖는 조합 백신
US8900626B2 (en) * 2011-06-20 2014-12-02 Senju Usa, Inc. Transdermal drug delivery system and method of using the same
CA2840989A1 (en) * 2011-07-06 2013-01-10 Novartis Ag Immunogenic combination compositions and uses thereof
SG11201400210RA (en) 2011-09-01 2014-03-28 Novartis Ag Adjuvanted formulations of staphylococcus aureus antigens
FI123955B (en) 2011-11-25 2014-01-15 Oncos Therapeutics Ltd Oncolytic adenovirus
WO2013131983A1 (en) 2012-03-07 2013-09-12 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
US9320748B2 (en) * 2012-03-07 2016-04-26 Novartis Ag Immunologically useful arginine salts
EP2822589A1 (en) 2012-03-07 2015-01-14 Novartis AG Adjuvanted formulations of rabies virus immunogens
EP2822581A2 (en) 2012-03-08 2015-01-14 Novartis AG Adjuvanted formulations of dtp booster vaccines
EP2674170B1 (en) 2012-06-15 2014-11-19 Invivogen Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids
WO2014016152A1 (en) 2012-07-27 2014-01-30 Institut National De La Sante Et De La Recherche Medicale Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
CN104736165A (zh) * 2012-08-31 2015-06-24 诺华股份有限公司 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
EP2732825B1 (en) 2012-11-19 2015-07-01 Invivogen Conjugates of a TLR7 and/or TLR8 agonist and a TLR2 agonist
CN103845731B (zh) * 2012-12-05 2015-12-02 复旦大学 抗st2/il-1r4抗体在制备防治瘙痒药物中的应用
US20140193484A1 (en) * 2013-01-10 2014-07-10 Sylvie Carine Bertholet Girardin Influenza virus immunogenic compositions and uses thereof
CA2899787A1 (en) 2013-02-01 2014-08-07 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor agonists
EP2769738B1 (en) 2013-02-22 2016-07-20 Invivogen Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists
BR112015028314A2 (pt) 2013-05-10 2017-09-19 Steinman Lawrence Prevenção do risco de narcolepsia em vacinas para gripe
CN104338129B (zh) * 2013-07-26 2017-05-24 中国科学院上海巴斯德研究所 雷帕霉素作为疫苗佐剂的用途及制备方法
TWI733652B (zh) 2014-07-11 2021-07-21 美商基利科學股份有限公司 用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑
MX2017003284A (es) 2014-09-16 2017-06-28 Gilead Sciences Inc Formas solidas de modulador de receptor tipo toll.
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
CN109415429B (zh) * 2016-06-30 2023-04-28 美国政府(由卫生和人类服务部的部长所代表) Herv-e反应性t细胞受体及使用方法
CA3036349A1 (en) * 2016-09-09 2018-03-15 Takeda Pharmaceutical Company Limited Cyclic compound having toll-like receptor 4 (tlr4) inhibitory activity
AR111760A1 (es) * 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
CN111447948B (zh) 2017-12-04 2025-09-02 英特维特国际股份有限公司 具有复制子颗粒和油佐剂的疫苗
JP7351859B2 (ja) * 2018-06-04 2023-09-27 アプロス セラピューティクス， インコーポレイテッド Ｔｌｒ７の調節に関係する疾患を処置するのに有用な酸性基を含むピリミジン化合物
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
EP3897637A1 (en) 2018-12-20 2021-10-27 Novartis AG Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
JP7287708B2 (ja) 2019-02-08 2023-06-06 プロジェニア インコーポレイテッド Ｔｏｌｌ－ｌｉｋｅ受容体７または８アゴニストとコレステロールの結合体およびその用途
WO2020165833A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
EA202192029A1 (ru) 2019-02-15 2021-10-27 Новартис Аг Замещенные производные 3-(1-оксоизоиндолин-2-ил)пиперидин-2,6-диона и варианты их применения
MX2021012201A (es) * 2019-04-05 2022-01-06 Sumitomo Pharma Co Ltd Adyuvante soluble en agua.
JP7590400B2 (ja) * 2019-07-03 2024-11-26 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗体薬物コンジュゲートの精製
CA3145765A1 (en) 2019-07-03 2021-01-07 Merck Patent Gmbh Glycoform purification
IL293889A (en) 2019-12-20 2022-08-01 Novartis Ag Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
EP4076445A1 (en) 2019-12-20 2022-10-26 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing toll-like receptor ("tlr") agonist prodrugs useful in the treatment of cancer and methods thereof
CN115666637A (zh) 2020-03-02 2023-01-31 蛋白科技先锋 基于病原体细胞壁骨架的模拟活病原体的纳米粒子及其制备方法
AU2021297099A1 (en) 2020-06-23 2023-01-05 Novartis Ag Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
WO2022009157A1 (en) 2020-07-10 2022-01-13 Novartis Ag Lhc165 and spartalizumab combinations for treating solid tumors
WO2022029573A1 (en) 2020-08-03 2022-02-10 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20230355750A1 (en) 2020-08-04 2023-11-09 Progeneer Inc. Kinetically acting adjuvant ensemble
JP2023536954A (ja) 2020-08-04 2023-08-30 プロジェニア インコーポレイテッド 活性化部位が一時的に不活性化したトール様受容体７または８作用薬と機能性薬物の結合体およびその用途
US20230346924A1 (en) 2020-08-04 2023-11-02 Progeneer Inc. Mrna vaccine comprising adjuvant capable of kinetic control
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
JP2024545235A (ja) * 2021-12-15 2024-12-05 上海翊石医薬科技有限公司 複素芳香族化合物、その製造方法及び使用
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
CN119497716A (zh) * 2023-06-15 2025-02-21 石药集团中奇制药技术（石家庄）有限公司 一种enpp1抑制剂的晶型

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009111337A1 (en) * 2008-03-03 2009-09-11 Irm Llc Compounds and compositions as tlr activity modulators
WO2010144734A1 (en) * 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
WO1997037026A1 (en) 1996-04-02 1997-10-09 Smithkline Beecham Corporation Novel compounds
WO1997043303A1 (en) 1996-05-14 1997-11-20 Smithkline Beecham Corporation Novel compounds
ES2277362T5 (es) 1996-10-31 2014-12-18 Human Genome Sciences, Inc. Antígenos y vacunas de streptococcus pneumoniae
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
WO1999010497A1 (en) 1997-08-21 1999-03-04 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Novel mutants of gram negative mucosal bacteria and application thereof in vaccines
JPH1180156A (ja) * 1997-09-04 1999-03-26 Hokuriku Seiyaku Co Ltd １−（置換アリール）アルキル−１ｈ−イミダゾピリジン−４−アミン誘導体
WO1999024578A2 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
CA2310217A1 (en) 1997-11-26 1999-06-03 Inhibitex, Inc. Extracellular matrix-binding proteins from staphylococcus aureus
CN1597694A (zh) 1998-01-14 2005-03-23 启龙股份公司 脑膜炎奈瑟氏球菌抗原
CA2328399A1 (en) 1998-04-23 1999-10-28 University Of Alabama At Birmingham Pneumococcal surface protein c(pspc), epitopic regions and strain selection thereof, and uses therefor
CA2330838C (en) 1998-05-01 2018-12-04 Chiron Corporation Neisseria meningitidis antigens and compositions
GB9810193D0 (en) 1998-05-12 1998-07-08 Smithkline Beecham Biolog Novel compounds
JP2002521058A (ja) 1998-07-27 2002-07-16 マイクロビアル テクニクス リミティッド 肺炎連鎖球菌由来の核酸及びタンパク質
JP2002531055A (ja) 1998-07-27 2002-09-24 マイクロビアル テクニクス リミティッド 肺炎連鎖球菌のタンパク質及び核酸分子
MXPA01002120A (es) 1998-08-31 2003-03-27 Trinity College Dublin Polipeptidos y polinucleotidos de estafilococo negativo a coagulasa.
KR100644953B1 (ko) 1998-08-31 2006-11-10 인히비텍스, 인코포레이티드 다성분 백신
CN1338005A (zh) 1998-10-09 2002-02-27 希龙公司 奈瑟球菌基因组序列及其用途
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
ATE422899T1 (de) 1998-12-21 2009-03-15 Medimmune Inc Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe
CN1198932C (zh) 1999-03-26 2005-04-27 科特克斯(Om)有限公司 肺炎链球菌抗原
DE60027890T2 (de) 1999-06-10 2007-04-19 Human Genome Sciences, Inc. Streptococcus pneumoniae proteine und impfstoffe
EP1075841A1 (en) 1999-08-13 2001-02-14 Erasmus Universiteit Rotterdam Pneumococcal vaccines
WO2001034642A2 (en) 1999-11-12 2001-05-17 University Of Iowa Research Foundation Control of neisserial membrane synthesis
PT1248647E (pt) 2000-01-17 2010-11-18 Novartis Vaccines & Diagnostics Srl Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b
DK2270030T3 (da) 2000-02-28 2012-08-13 Novartis Vaccines & Diagnostic Heterolog ekspression af Neisseria-proteiner
KR20020097200A (ko) 2000-03-21 2002-12-31 엘리트라 파마슈티컬즈, 인코포레이티드 원핵세포에서의 필수유전자의 동정
WO2001081380A2 (en) 2000-04-27 2001-11-01 Medimmune, Inc. Immunogenic pneumococcal protein and vaccine compositions thereof
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
US6495079B1 (en) 2000-06-28 2002-12-17 Prisma Fibers, Inc. Process to prepare polymeric fibers with improved color and appearance
WO2002002606A2 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
WO2002008426A2 (en) 2000-07-20 2002-01-31 Hansa Medical Ab Fh-binding protein of streptococcus pneumoniae
CA2416137C (en) 2000-07-27 2013-01-29 Dan Granoff Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
AU8743001A (en) 2000-08-28 2002-03-13 Aventis Pasteur Moraxella polypeptides and corresponding dna fragments and uses thereof
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
AU2001295795A1 (en) 2000-10-26 2002-05-06 Imperial College Innovations Ltd. Streptococcal genes
MX357775B (es) 2000-10-27 2018-07-20 J Craig Venter Inst Inc Acidos nucleicos y proteinas de los grupos a y b de estreptococos.
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103424D0 (en) 2001-02-12 2001-03-28 Chiron Spa Gonococcus proteins
WO2002077183A2 (en) 2001-03-21 2002-10-03 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0108079D0 (en) 2001-03-30 2001-05-23 Microbial Technics Ltd Protein
WO2002094851A2 (en) 2001-05-18 2002-11-28 The Government Of The United States Of America, Asrepresented By The Secretary, Department Of Healthand Human Services, Centers For Disease Control And Prevention, Technology Transfer Office Peptide vaccines against group a streptococci
US6841154B2 (en) 2001-06-15 2005-01-11 Inhibitex, Inc. Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and Staphylococcus aureus
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
CA2453937C (en) 2001-08-02 2013-05-14 University Of Sheffield Antigenic polypeptides
US20050106162A1 (en) 2001-12-12 2005-05-19 Guido Grandi Immunisation against chlamydia trachomatis
GB0203403D0 (en) 2002-02-13 2002-04-03 Chiron Spa Chlamydia cytotoxic-T cell epitopes
EP2275128B1 (en) 2002-04-02 2013-10-16 Ben Gurion University Of The Negev Research And Development Authority Protein-based streptococcus pneumoniae vaccines
GB0210128D0 (en) 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
KR20050010040A (ko) 2002-06-11 2005-01-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
GB0213622D0 (en) 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
NZ574530A (en) 2002-08-02 2010-12-24 Glaxosmithkline Biolog Sa Vaccine compositions comprising L2 and/or L3 immunotype lipooligosaccharides from lgtB-neisseria minigitidis
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
WO2004041157A2 (en) 2002-09-13 2004-05-21 Chiron Corporation Group b streptococcus vaccine
ES2775098T3 (es) 2002-10-11 2020-07-23 Glaxosmithkline Biologicals Sa Vacunas de polipéptidos para protección amplia contra linajes meningocócicos hipervirulentos
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
ES2529736T3 (es) 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS
EP2314718A1 (en) 2003-04-15 2011-04-27 Intercell AG S. pneumoniae antigens
DE10327439A1 (de) * 2003-06-18 2005-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel
CN1812809A (zh) 2003-06-26 2006-08-02 希龙公司 用于沙眼衣原体的免疫原性组合物
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
EP1648500B1 (en) 2003-07-31 2014-07-09 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for streptococcus pyogenes
WO2005079315A2 (en) 2004-02-18 2005-09-01 Merck & Co., Inc. Polypeptides for inducing a protective immune response against staphylococcus aureus
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
BRPI0515520A (pt) 2004-09-22 2008-07-29 Glaxosmithkline Biolog Sa composição imunogênica, vacina, métodos de preparar uma vacina e de prevenir ou tratar infecção estafilocócica, e, uso de composição imunogênica
RU2432962C2 (ru) 2005-01-27 2011-11-10 Чилдрен'З Хоспитал Энд Рисерч Сентер Эт Окленд Вакцины с использованием везикул на основе gna 1870 широкого спектра действия для профилактики заболеваний, вызываемых neisseria meningitidis
EP1977009B1 (en) 2005-12-27 2016-08-17 Obetech, LLC Adipogenic adenoviruses as a biomarker for disease
EP2368570A3 (en) 2006-01-18 2012-05-02 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
WO2007116322A2 (en) 2006-02-17 2007-10-18 Novartis Ag Purification of bacterial antigens
WO2007109813A1 (en) * 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
AR060188A1 (es) 2006-03-30 2008-05-28 Glaxosmithkline Biolog Sa Procedimiento de conjugacion
BRPI0710210A2 (pt) 2006-03-30 2011-05-24 Glaxomithkline Biolog S A composição imunogênica, vacina, métodos para preparar a vacina, e para prevenir ou tratar infecção estafilocócica, uso da composição imunogênica, e, processo para conjugar oligassacarìdeo ou polissacarìdeo capsular
CN102760226B (zh) * 2011-04-29 2015-07-01 贵州师范大学 一种基于实心正方形的试卷客观题答题卡定位方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009111337A1 (en) * 2008-03-03 2009-09-11 Irm Llc Compounds and compositions as tlr activity modulators
WO2010144734A1 (en) * 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines

Also Published As

Publication number Publication date
BR112012004696B8 (pt) 2021-05-25
LT2473508T (lt) 2017-06-12
EA020962B1 (ru) 2015-03-31
WO2011049677A1 (en) 2011-04-28
HRP20170707T1 (hr) 2017-07-14
CY1119618T1 (el) 2018-04-04
JP5525614B2 (ja) 2014-06-18
TW201113281A (en) 2011-04-16
CN102712636A (zh) 2012-10-03
EP2473508A1 (en) 2012-07-11
EA201200406A1 (ru) 2012-09-28
AU2010308524A1 (en) 2012-04-19
BR112012004696B1 (pt) 2021-01-05
ES2627669T3 (es) 2017-07-31
CL2012000535A1 (es) 2012-08-17
PL2473508T3 (pl) 2017-08-31
US9045470B2 (en) 2015-06-02
US20110053893A1 (en) 2011-03-03
US20150225432A1 (en) 2015-08-13
IN2012DN02736A (forum.php) 2015-09-11
BR112012004696A2 (pt) 2017-05-23
AR078153A1 (es) 2011-10-19
MX2012002654A (es) 2012-03-26
JO3257B1 (ar) 2018-09-16
HUE032323T2 (en) 2017-09-28
CA2772657C (en) 2015-11-24
SI2473508T1 (sl) 2017-07-31
PE20121156A1 (es) 2012-08-23
CA2772657A1 (en) 2011-04-28
TWI445708B (zh) 2014-07-21
UY32874A (es) 2011-04-29
DK2473508T3 (en) 2017-06-06
PT2473508T (pt) 2017-05-29
CN102712636B (zh) 2014-11-05
SMT201700276T1 (it) 2017-07-18
EP2473508B1 (en) 2017-03-08
JP2013503884A (ja) 2013-02-04

Similar Documents

Publication Publication Date Title
AU2010308524B2 (en) Compounds and compositions as TLR activity modulators
AU2010290896B2 (en) Immunogenic compositions including TLR activity modulators
US9365506B2 (en) Compounds and compositions as TLR2 agonists
US8895577B2 (en) Compounds and compositions as TLR activity modulators
WO2011057148A1 (en) Compounds and compositions as tlr-7 activity modulators
HK1172015B (en) Compounds and compositions as tlr activity modulators
HK1172015A (en) Compounds and compositions as tlr activity modulators

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: NOVARTIS AG

Free format text: FORMER OWNER WAS: IRM LLC; NOVARTIS AG